NASDAQ:PBM Psyence Biomedical (PBM) Stock Price, News & Analysis → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free PBM Stock Alerts $1.06 +0.03 (+2.91%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$0.97▼$1.0850-Day Range$0.55▼$2.1152-Week Range$0.51▼$4.31Volume139,938 shsAverage Volume3.30 million shsMarket Capitalization$9.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Psyence Biomedical alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Psyence Biomedical Stock (NASDAQ:PBM)Newcourt Acquisition Corp is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. Newcourt Acquisition Corp is based in Oakland, California.Read More PBM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBM Stock News HeadlinesApril 17, 2024 | finance.yahoo.comPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)April 17, 2024 | globenewswire.comPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)May 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!April 16, 2024 | globenewswire.comPsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialApril 8, 2024 | tmcnet.comPsyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin TrialApril 8, 2024 | globenewswire.comPsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialMarch 28, 2024 | finanznachrichten.dePsyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessMarch 26, 2024 | globenewswire.comPsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessMay 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!March 24, 2024 | morningstar.comPsyence Biomedical Ltd PBMMarch 22, 2024 | seekingalpha.comPBM Psyence Biomedical Ltd.March 21, 2024 | uk.investing.comPsyence Biomedical Ltd (PBM)March 18, 2024 | stockhouse.comPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinMarch 18, 2024 | globenewswire.comPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinMarch 17, 2024 | uk.investing.comPsyence Biomedical faces Nasdaq delisting over market valueMarch 15, 2024 | globenewswire.comPsyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held SharesMarch 12, 2024 | globenewswire.comPsyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb StudyMarch 12, 2024 | globenewswire.comPsyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future MilestonesMarch 11, 2024 | benzinga.comPsyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In AustraliaMarch 8, 2024 | investorplace.comWhy Is Psyence Biomedical (PBM) Stock Up 90% Today?See More Headlines Receive PBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psyence Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:PBM Previous SymbolNASDAQ:PBM CUSIPN/A CIK1985062 WebN/A Phone510-214-3750FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares8,788,000Free Float8,472,000Market Cap$9.32 million OptionableN/A Beta-0.11 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key CompetitorsNewGenIvf GroupNASDAQ:NIVFCERo TherapeuticsNASDAQ:CEROBioCardiaNASDAQ:BCDAGuardion Health SciencesNASDAQ:GHSIGalera TherapeuticsNASDAQ:GRTXView All Competitors PBM Stock Analysis - Frequently Asked Questions How have PBM shares performed in 2024? Psyence Biomedical's stock was trading at $2.35 at the beginning of 2024. Since then, PBM stock has decreased by 54.9% and is now trading at $1.06. View the best growth stocks for 2024 here. Are investors shorting Psyence Biomedical? Psyence Biomedical saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 242,300 shares, a decline of 27.7% from the March 31st total of 335,300 shares. Based on an average daily volume of 3,450,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 5.2% of the shares of the company are sold short. View Psyence Biomedical's Short Interest. What ETF holds Psyence Biomedical's stock? AdvisorShares Psychedelics ETF holds 325,708 shares of PBM stock, representing 3.78% of its portfolio. How do I buy shares of Psyence Biomedical? Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PBM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
